TPD52 and prostate cancer: The research by Fan et al. indicates that ERK1/2-mediated phosphorylation of PrLZ at the Ser40 site stabilizes PrLZ by disrupting its binding to SPOP, thereby facilitating the proliferation and migration of prostate cancer cells (Table 1) (Fan et al., 2022).